BLISS-LN
2020
Belimumab in Lupus Nephritis
In 448 patients with active lupus nephritis, adding belimumab to standard therapy increased renal response at week 104 compared with placebo.
Result
Efficacy: Primary efficacy renal response at week 104OR 1.55 (CI 1.04-2.32) · P = 0.03
Below 1 favours placebo, above 1 favours belimumab to standard therapy.
- Absolute difference
- 11 points
- NNT
- 10
Absolute difference and NNT are derived from the event rates.
Also reported: Renal-related event or death HR 0.51.
- Subtopic
- Lupus nephritis
- Design
- Phase 3 double-blind RCT
- Relevance
- Important: one of several pillars.
- Source
- Furie R, et al. N Engl J Med. 2020;383(12):1117-1128.doi 10.1056/NEJMoa2001180
Discussion & critique
First biologic approved specifically for lupus nephritis; KDIGO 2024 add-on for active disease.